Literature DB >> 19956501

Synergistic effect of ionizing radiation and beta-Lapachone against RKO human colon adenocarcinoma cells.

Eun Jung Kim1, In-Mi Ji, Ki-Jung Ahn, Eun Kyung Choi, Heon-Jin Park, Byung Uk Lim, Chang W Song, Heon Joo Park.   

Abstract

PURPOSE: To reveal the interaction between beta-Lapachone (beta-lap) and ionizing radiation in causing cell death in RKO human colon adenocarcinoma cells, and to elucidate the potential usefulness of combined beta-lap treatment and radiotherapy for cancer treatment.
MATERIALS AND METHODS: The cytotoxicities of various treatments were determined in vitro using clonogenic and apoptotic cell death. The changes in cell cycle distribution were studied using flow cytometry and an in vitro kinase assay. The tumor growth was studied using RKO tumors grown s.c. in the hind leg BALB/c- nuslc nude mice.
RESULTS: beta-Lap caused clonogenic cell death and rapid apoptosis in RKO cells in vitro, in a dose dependent manner. The repair of sublethal radiation damage was almost completely inhibited when cells were maintained in beta-lap during the interval between the two-dose irradiation. Flow cytometry study demonstrated that beta-lap induced apoptosis, independent of the cell cycle phase, and completely prohibited the induction of radiation-induced G2 arrest in irradiated cells. The prohibition of radiation-induced G2 arrest is unclear, but may be related to the profound suppression of the p53, p21 and cyclin B1-Cdc2 kinase activities observed in cells treated with beta-lap. The combination of beta-lap and radiation markedly enhanced the radiation-induced growth suppression of tumors.
CONCLUSION: beta-Lap is cytotoxic against RKO cells, both in vitro and in vivo, and also sensitized cells to ionizing radiation by inhibiting sublethal radiation damage repair. beta-lap is potentially useful as a potent anti-cancer chemotherapy drug and potent radiosensitizer against cancer cells.

Entities:  

Keywords:  Ionizing radiation; NQO1; RKO cells; Radiosensitization; β-Lapachone

Year:  2005        PMID: 19956501      PMCID: PMC2785409          DOI: 10.4143/crt.2005.37.3.183

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  24 in total

1.  Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.

Authors:  Robert J Griffin; Brent W Williams; Robert Wild; Julie M Cherrington; Heonjoo Park; Chang W Song
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

2.  Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.

Authors:  D Siegel; W A Franklin; D Ross
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

3.  Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.

Authors:  Heon Joo Park; Ki-Jung Ahn; Seung-Do Ahn; Eunkyung Choi; Sang Wook Lee; Brent Williams; Eun Jung Kim; Robert Griffin; Erik A Bey; William G Bornmann; Jinming Gao; Heon Jin Park; David A Boothman; Chang W Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-01-01       Impact factor: 8.013

4.  Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.

Authors:  S Miyamoto; T T Huang; S Wuerzberger-Davis; W G Bornmann; J J Pink; C Tagliarino; T J Kinsella; D A Boothman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 6.499

5.  NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.

Authors:  J J Pink; S M Planchon; C Tagliarino; M E Varnes; D Siegel; D A Boothman
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.486

6.  Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.

Authors:  Youzhi Li; Xiangao Sun; J Thomas LaMont; Arthur B Pardee; Chiang J Li
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 12.779

7.  Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells.

Authors:  S M Planchon; S M Wuerzberger-Davis; J J Pink; K A Robertson; W G Bornmann; D A Boothman
Journal:  Oncol Rep       Date:  1999 May-Jun       Impact factor: 4.136

8.  Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.

Authors:  D A Boothman; D K Trask; A B Pardee
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 13.312

9.  Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.

Authors:  S M Wuerzberger; J J Pink; S M Planchon; K L Byers; W G Bornmann; D A Boothman
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 13.312

10.  Beta-lapachone greatly enhances MMS lethality to human fibroblasts.

Authors:  R J Boorstein; A B Pardee
Journal:  Biochem Biophys Res Commun       Date:  1984-02-14       Impact factor: 3.322

View more
  4 in total

1.  Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.

Authors:  Ganji Purnachandra Nagaraju; Batoul Farran; Matthew Farren; Gayathri Chalikonda; Christina Wu; Gregory B Lesinski; Bassel F El-Rayes
Journal:  Cancer       Date:  2020-05-08       Impact factor: 6.860

2.  Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Authors:  Muhammad Shaalan Beg; Xiumei Huang; Molly A Silvers; David E Gerber; Joyce Bolluyt; Venetia Sarode; Farjana Fattah; Ralph J Deberardinis; Matthew E Merritt; Xian-Jin Xie; Richard Leff; Daniel Laheru; David A Boothman
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 2.885

3.  Enhancement of radiation effect using beta-lapachone and underlying mechanism.

Authors:  Ki Jung Ahn; Hyung Sik Lee; Se Kyung Bai; Chang Won Song
Journal:  Radiat Oncol J       Date:  2013-06-30

4.  β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.

Authors:  E J Park; K-J Min; T-J Lee; Y H Yoo; Y-S Kim; T K Kwon
Journal:  Cell Death Dis       Date:  2014-05-15       Impact factor: 9.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.